sea-cd40
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2015 (NCT02376699)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 1
- Head and Neck Neoplasms · Phase 1
- Hodgkin Disease · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Melanoma · Phase 2
- Neoplasm Metastasis · Phase 1
- Neoplasms, Squamous Cell · Phase 1
- Pancreatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- sea-cd40
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04993677 | Phase 2 | Oct 6, 2021 | Merck, Seattle Genetics |
| NCT02376699 | Phase 1 | Feb 1, 2015 | Seattle Genetics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Seattle Genetics | For profit | 2 | 2 | 2 | 2015 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1